OBJECTIVE: to know ambulatory blood pressure control status of diabetic patients with hypertension and provide information for antihypertensive therapy.
目的：了解糖尿病合并高血压患者的动态血压控制状况，为降压治疗提供依据。
Objective: To study the relationship between hypertension and insulin resistance and plasma adrenomedullin endothelin changes in diabetic patients with hypertension.
目的：探讨胰岛素抵抗、血浆肾上腺髓质素、内皮素与糖尿病合并高血压的关系。
The changes, however, "did not lead to substantially better hypertension control for diabetics compared with non-diabetic patients," the researchers concluded.
这些策略上的改变，“同非糖尿病患者相比，并未改善糖尿病患者的高血压控制，”研究人员总结道。
Conclusion:Allele T of AGT gene M235T, the longer diabetes duration and history of hypertension were associated with higher risk of nephropathy in type 2 diabetic patients.
结论：AGT基因235T等位基因、糖尿病病程长、既往高血压史均可增加2型糖尿病患者合并肾病的危险；
Method: Case control study was used to observe the changes of serum lipid levels in type 2 diabetes patients and type 2 diabetic nephropathy patients with hypertension or normotension.
方法：采用病例对照研究的方法观察2型糖尿病、2型糖尿病肾病合并高血压和不合并高血压患者血脂水平的变化。
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria.
预测因子与2型糖尿病肾病和高血压患者心血管事件的预测因子：蛋白尿因素。
CONCLUSION Telmisartan is superior to losartan in reducing proteinuria in diabetic nephropathy patients with hypertension, despite a similar reduction in blood pressure.
结论：替米沙坦减轻糖尿病肾病患者蛋白尿优于氯沙坦。
Methods There 36 diabetic nephropathy patients complicated with refractory hypertension were treated with two different therapies and the results were observed before and after the treatment.
方法对36例糖尿病肾病合并顽固性高血压患者随机分为治疗组和对照组，观察两组治疗前后降压情况、副作用和实验证据变化。
Methods There 36 diabetic nephropathy patients complicated with refractory hypertension were treated with two different therapies and the results were observed before and after the treatment.
方法对36例糖尿病肾病合并顽固性高血压患者随机分为治疗组和对照组，观察两组治疗前后降压情况、副作用和实验证据变化。
应用推荐